← Leaderboards
David J. Fink
University Of Pittsburgh At Pittsburgh
$11,160,913
Attributed
$11,160,913
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$11,160,913 · 5
VA$0 · 2
By mechanism
R01$4,717,855 · 2
P01$3,338,040 · 2
U01$3,105,018 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Bradley K Taylor$17,950,936
- Naoki Yoshimura$12,168,895
- Joseph C. Glorioso$19,383,290
- Micheal Giuliani$0
- Michael B Chancellor$7,406,767
Others in their field
Top investigators on “Hsv Vector”
- Joseph C. Glorioso · University Of Pittsburgh At Pittsburgh$18,811,049
- Michael C Keefer · University Of Rochester$11,606,890
- Robert L Martuza · Massachusetts General Hospital$10,885,369
- David M Knipe · Harvard Medical School$9,431,785
- Estuardo Aguilar-Cordova · Advantagene, Inc$9,013,464
- Howard J. Federoff · University Of Rochester$8,582,813
Research focus
Hsv VectorAnimalsBaseSimplexvirusVectorNeuronsNeuropathySpinal GangliaPreventPeptidesPre-ClinicalFundingPainRodent ModelNerveDiabeticDiabetic NeuropathiesGene TransferNeurotrophic FactorDoseRattusDiabetes MellitusResponseTransfection /Expression Vector
Grant awards (33)
Regulatable Gene Expression for Prevention of Neuropathy$0
I01 · FY2017 · VA · contact PI
Regulatable Gene Expression for Prevention of Neuropathy$0
I01 · FY2016 · VA · contact PI
Regulatable Gene Expression for Prevention of Neuropathy$0
I01 · FY2015 · VA · contact PI
HSV GAD for Painful Diabetic Neuropathy$0
I01 · FY2014 · VA · contact PI
HSV GAD for Painful Diabetic Neuropathy$0
I01 · FY2014 · VA · contact PI
Regulatable Gene Expression for Prevention of Neuropathy$0
I01 · FY2014 · VA · contact PI
Preclinical Development of an NT3-expressing HSV Vector$1,047,123
U01 · FY2013 · NS · contact PI
Preclinical Development of an NT3-expressing HSV Vector$1,056,121
U01 · FY2012 · NS · contact PI
Gene Transfer for Prevention of Diabetic Neuropathy$325,850
R01 · FY2012 · NS · contact PI
HSV GAD for Painful Diabetic Neuropathy$0
I01 · FY2012 · VA · contact PI
Preclinical Development of an NT3-expressing HSV Vector$1,001,774
U01 · FY2011 · NS · contact PI
Gene Transfer for Prevention of Diabetic Neuropathy$325,850
R01 · FY2011 · NS · contact PI
PAINFUL DIABETIC NEUROPATHY$490,854
P01 · FY2010 · DK · contact PI
Gene Transfer for Prevention of Diabetic Neuropathy$329,176
R01 · FY2010 · NS · contact PI
PAINFUL DIABETIC NEUROPATHY$481,405
P01 · FY2009 · DK · contact PI
Gene Transfer for Prevention of Diabetic Neuropathy$332,500
R01 · FY2009 · NS · contact PI
PAINFUL DIABETIC NEUROPATHY$467,411
P01 · FY2008 · DK · contact PI
Gene Transfer for Prevention of Diabetic Neuropathy$332,500
R01 · FY2008 · NS · contact PI
PAINFUL DIABETIC NEUROPATHY$349,554
P01 · FY2007 · DK · contact PI
PAINFUL DIABETIC NEUROPATHY$361,629
P01 · FY2006 · DK · contact PI
Gene Therapy for Pain$456,299
R01 · FY2005 · NS
Gene Transfer for Prevention of Diabetic Neuropathy$305,199
R01 · FY2005 · NS
Gene Therapy for Pain$443,008
R01 · FY2004 · NS
Gene Transfer for Prevention of Diabetic Neuropathy$319,085
R01 · FY2004 · NS
Gene Therapy for Pain$431,130
R01 · FY2003 · NS
Gene Therapy for Pain$419,898
R01 · FY2002 · NS
Gene Transfer for Prevention of Diabetic Neuropathy$313,829
R01 · FY2002 · NS
CORE--VECTOR DESIGN AND PRODUCTION$382,503
P01 · FY2001 · NS
GENE TRANSFER FOR PREVENTION OF DIABETIC NEUROPATHY$194,600
R01 · FY2001 · NS
CORE--VECTOR DESIGN AND PRODUCTION$173,158
P01 · FY2001 · NS
CORE--VECTOR DESIGN AND PRODUCTION$382,503
P01 · FY2000 · NS
CORE--VECTOR DESIGN AND PRODUCTION$249,023
P01 · FY2000 · NS
GENE TRANSFER FOR PREVENTION OF DIABETIC NEUROPATHY$188,931
R01 · FY2000 · NS